Paul W. Shabram
Hoofd Techniek/Wetenschap/O&O bij BIORA THERAPEUTICS, INC.
Actieve functies van Paul W. Shabram
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| BIORA THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 25-04-2022 | - |
Loopbaan van Paul W. Shabram
Eerdere bekende functies van Paul W. Shabram
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| EMERGENT BIOSOLUTIONS INC. | Hoofd Techniek/Wetenschap/O&O | - | - |
| Ventana Biosciences, Inc. | Oprichter | - | - |
Emergent Travel Health, Inc.
 Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01-07-2007 | - |
Opleiding van Paul W. Shabram
| University of California, Santa Cruz | Undergraduate Degree |
| University of Phoenix | Masters Business Admin |
Statistieken
Internationaal
| Verenigde Staten | 7 |
Operationeel
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Sectoraal
| Consumer Services | 3 |
| Technology Services | 2 |
| Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| EMERGENT BIOSOLUTIONS INC. | Health Technology |
| BIORA THERAPEUTICS, INC. | Health Services |
| Bedrijven in privébezit | 2 |
|---|---|
Emergent Travel Health, Inc.
Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | Technology Services |
| Ventana Biosciences, Inc. |
- Beurs
- Insiders
- Paul W. Shabram
- Ervaring
